Loading
Life sciences · Journal article
Scientific Reports · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity threatens both human and poultry health, with intensive farming exacerbating metabolic disorders such as fatty liver disease. Safe and effective nutritional interventions remain limited. Carbamoyl aspartate (CA), a pyrimidine biosynthesis intermediate, reduced hepatic triglyceride (TG) accumulation in vitro (HepG2 cells) and in vivo (broilers). In broilers fed a high-fat diet (HFD), CA supplementation (800 mg/kg) significantly decreased liver weight, hepatic TG/total cholesterol (TC) levels, and abdominal fat deposition ( P < 0.05), while improving meat color and increasing muscle yield. Network pharmacology identified 22 candidate targets linking CA to lipid metabolism, with PDE4B showing the most favorable predicted docking interaction among the screened candidates. The compound-target-pathway-disease network suggested potential multi-target molecular associations. These findings support the potential of CA as a nutritional intervention for HFD-associated lipid metabolic disturbances in broilers, while the predicted molecular mechanisms require further validation.